brinzolamide 10 MG/ML Ophthalmic Suspension [Azopt]

What the CMS Formulary Data Shows for brinzolamide 10 MG/ML Ophthalmic Suspension [Azopt]

Per the CMS 2026 Part D formulary file, brinzolamide 10 MG/ML Ophthalmic Suspension [Azopt] (RxNorm concept RXCUI 213272, generic name brinzolamide) appears on 4 distinct formulary files spanning 44 Medicare Part D plan offerings - 0.9% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.8.

Real-world access to brinzolamide 10 MG/ML Ophthalmic Suspension [Azopt] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 43,939 Part D beneficiaries filled brinzolamide 10 MG/ML Ophthalmic Suspension [Azopt] in 2023, with total plan-and-beneficiary spending of $52,752,444 and an average per-beneficiary annual cost of $1,200.58. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry brinzolamide 10 MG/ML Ophthalmic Suspension [Azopt] today.